search
Back to results

Alvimopan and Ileus in PSF

Primary Purpose

Ileus, Spinal Fusion

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Alvimopan
Placebo
Sponsored by
Washington University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ileus focused on measuring Alvimopan, Ileus, Posterior spinal fusion

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • adult patients undergoing elective PSF of at least 5 levels and/or fixation to pelvis

Exclusion Criteria:

  • pregnant women
  • ischemic heart disease
  • chronic liver or renal disease
  • prior bowel resection
  • presence of colostomy or ileostomy
  • gastroparesis
  • complete bowel obstruction
  • inflammatory bowel disease (ulcerative colitis or Crohn's disease).

Sites / Locations

  • Barnes Jewish Hospital / Washington University in St. Louis School of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Alvimopan

Placebo - Sugar Pill

Arm Description

Alvimopan 12mg once orally two hours prior to surgery and then 2 mg orally twice a day until post-operative day (POD) seven.

Placebo Sugar Pill orally two hours prior to surgery and then one sugar pill orally twice a day until post-operative day (POD) seven

Outcomes

Primary Outcome Measures

Recovery of Bowel Function
To determine the effect of alvimopan on the recovery of bowel function as determined by time to first bowel movement in patients undergoing posterior spinal fusion. The effect size calculated may guide a larger, multicenter randomized controlled study. Time was measured from wound closure to bowel movement.
Length of Hospital Stay
To determine the effect of alvimopan on overall length of hospital stay in patients undergoing PSF.

Secondary Outcome Measures

Complications and Adverse Event
Number of patients with complication/adverse event.

Full Information

First Posted
August 13, 2014
Last Updated
May 15, 2019
Sponsor
Washington University School of Medicine
Collaborators
Orthopedic Research and Education Foundation, Barnes-Jewish Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02218190
Brief Title
Alvimopan and Ileus in PSF
Official Title
A Randomized Trial of Alvimopan for the Reduction of Ileus After Long Posterior Spinal Fusion
Study Type
Interventional

2. Study Status

Record Verification Date
May 2019
Overall Recruitment Status
Completed
Study Start Date
August 2014 (undefined)
Primary Completion Date
January 2016 (Actual)
Study Completion Date
January 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Washington University School of Medicine
Collaborators
Orthopedic Research and Education Foundation, Barnes-Jewish Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to determine with Alvimopan reduces the incidence of post operative ileus in patients who undergo posterior spinal fusion.
Detailed Description
Posterior spinal fusion (PSF) is a common orthopaedic procedure associated with a high incidence of post-operative ileus (POI) and concomitant increased length of hospital stay (LOHS). POI is exacerbated by high dose opiate consumption often required by these patients post-operatively. We propose a randomized, double-blinded, placebo-controlled pilot trial studying the use of alvimopan, a peripherally-acting mu-opioid receptor antagonist known to reduce POI in bowel resection. We hypothesize that alvimopan will shorten POI in spine fusion patients without negatively affecting post-operative pain control. Treatment efficacy will be assessed by recording time to first bowel movement, time to hospital discharge, and post-operative pain control. We hypothesize that acute administration of alvimopan, a peripherally-acting mu-opioid antagonist, shortens the duration of post-operative ileus (POI) in patients undergoing long-segment (5 or greater thoracolumbar levels) posterior spinal fusion (PSF). The study will be a randomized, double-blinded, placebo-controlled pilot trial. Reducing the morbidity of POI in patients undergoing PSF will decrease hospital stay and costs, and also improve patient satisfaction and post-operative care after major orthopaedic surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ileus, Spinal Fusion
Keywords
Alvimopan, Ileus, Posterior spinal fusion

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Alvimopan
Arm Type
Experimental
Arm Description
Alvimopan 12mg once orally two hours prior to surgery and then 2 mg orally twice a day until post-operative day (POD) seven.
Arm Title
Placebo - Sugar Pill
Arm Type
Placebo Comparator
Arm Description
Placebo Sugar Pill orally two hours prior to surgery and then one sugar pill orally twice a day until post-operative day (POD) seven
Intervention Type
Drug
Intervention Name(s)
Alvimopan
Other Intervention Name(s)
Entereg
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Sugar Pill
Primary Outcome Measure Information:
Title
Recovery of Bowel Function
Description
To determine the effect of alvimopan on the recovery of bowel function as determined by time to first bowel movement in patients undergoing posterior spinal fusion. The effect size calculated may guide a larger, multicenter randomized controlled study. Time was measured from wound closure to bowel movement.
Time Frame
14 days or until hospital discharge whichever occurs first
Title
Length of Hospital Stay
Description
To determine the effect of alvimopan on overall length of hospital stay in patients undergoing PSF.
Time Frame
14 days or until hospital discharge whichever occurs first
Secondary Outcome Measure Information:
Title
Complications and Adverse Event
Description
Number of patients with complication/adverse event.
Time Frame
14 days or until hospital discharge, which ever occurs first

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: adult patients undergoing elective PSF of at least 5 levels and/or fixation to pelvis Exclusion Criteria: pregnant women ischemic heart disease chronic liver or renal disease prior bowel resection presence of colostomy or ileostomy gastroparesis complete bowel obstruction inflammatory bowel disease (ulcerative colitis or Crohn's disease).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael P Kelly, MD
Organizational Affiliation
Department of Orthopedic Surgery - Washington University in St. Louis School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Barnes Jewish Hospital / Washington University in St. Louis School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63108
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
11755891
Citation
Kehlet H, Holte K. Review of postoperative ileus. Am J Surg. 2001 Nov;182(5A Suppl):3S-10S. doi: 10.1016/s0002-9610(01)00781-4.
Results Reference
background
PubMed Identifier
17909274
Citation
Senagore AJ. Pathogenesis and clinical and economic consequences of postoperative ileus. Am J Health Syst Pharm. 2007 Oct 15;64(20 Suppl 13):S3-7. doi: 10.2146/ajhp070428.
Results Reference
background
PubMed Identifier
16076918
Citation
Leslie JB. Alvimopan for the management of postoperative ileus. Ann Pharmacother. 2005 Sep;39(9):1502-10. doi: 10.1345/aph.1E615. Epub 2005 Aug 2.
Results Reference
background
PubMed Identifier
15135926
Citation
Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett. 2004 May 6;361(1-3):192-5. doi: 10.1016/j.neulet.2003.12.004.
Results Reference
background
PubMed Identifier
12656645
Citation
Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63(7):649-71. doi: 10.2165/00003495-200363070-00003.
Results Reference
background
PubMed Identifier
15357847
Citation
Sternini C, Patierno S, Selmer IS, Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil. 2004 Oct;16 Suppl 2:3-16. doi: 10.1111/j.1743-3150.2004.00553.x.
Results Reference
background
PubMed Identifier
15017498
Citation
Behm B, Stollman N. Postoperative ileus: etiologies and interventions. Clin Gastroenterol Hepatol. 2003 Mar;1(2):71-80. doi: 10.1053/cgh.2003.50012.
Results Reference
background
PubMed Identifier
11091234
Citation
Holte K, Kehlet H. Postoperative ileus: a preventable event. Br J Surg. 2000 Nov;87(11):1480-93. doi: 10.1046/j.1365-2168.2000.01595.x.
Results Reference
background
PubMed Identifier
8057274
Citation
Zimmerman DM, Gidda JS, Cantrell BE, Schoepp DD, Johnson BG, Leander JD. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem. 1994 Jul 22;37(15):2262-5. doi: 10.1021/jm00041a003.
Results Reference
background
PubMed Identifier
15906123
Citation
Delaney CP, Weese JL, Hyman NH, Bauer J, Techner L, Gabriel K, Du W, Schmidt WK, Wallin BA; Alvimopan Postoperative Ileus Study Group. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum. 2005 Jun;48(6):1114-25; discussion 1125-6; author reply 1127-9. doi: 10.1007/s10350-005-0035-7.
Results Reference
background
PubMed Identifier
11180040
Citation
Liu SS, Hodgson PS, Carpenter RL, Fricke JR Jr. ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther. 2001 Jan;69(1):66-71. doi: 10.1067/mcp.2001.112680.
Results Reference
background
PubMed Identifier
16333556
Citation
Viscusi ER, Goldstein S, Witkowski T, Andonakakis A, Jan R, Gabriel K, Du W, Techner L, Wallin B. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc. 2006 Jan;20(1):64-70. doi: 10.1007/s00464-005-0104-y. Epub 2005 Dec 7. Erratum In: Surg Endosc. 2006 Mar;20(3):537.
Results Reference
background
PubMed Identifier
15383800
Citation
Wolff BG, Michelassi F, Gerkin TM, Techner L, Gabriel K, Du W, Wallin BA; Alvimopan Postoperative Ileus Study Group. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg. 2004 Oct;240(4):728-34; discussion 734-5. doi: 10.1097/01.sla.0000141158.27977.66.
Results Reference
background
PubMed Identifier
19086236
Citation
Buchler MW, Seiler CM, Monson JR, Flamant Y, Thompson-Fawcett MW, Byrne MM, Mortensen ER, Altman JF, Williamson R. Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther. 2008 Aug 1;28(3):312-25. doi: 10.1111/j.1365-2036.2008.03696.x.
Results Reference
background
PubMed Identifier
17617331
Citation
Wolff BG, Viscusi ER, Delaney CP, Du W, Techner L. Patterns of gastrointestinal recovery after bowel resection and total abdominal hysterectomy: pooled results from the placebo arms of alvimopan phase III North American clinical trials. J Am Coll Surg. 2007 Jul;205(1):43-51. doi: 10.1016/j.jamcollsurg.2007.02.026. Epub 2007 May 17.
Results Reference
background
Links:
URL
https://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/021775s000_sumr.pdf
Description
Summary Review for Regulatory Action

Learn more about this trial

Alvimopan and Ileus in PSF

We'll reach out to this number within 24 hrs